ArriVent BioPharma, Inc. AVBP Income Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| $153.35M+94.1% | $79M+21.8% | ||
| $24.18M+58.0% | $15.3M+57.7% | ||
| $177.53M+88.2% | $94.31M+26.4% | ||
| -$177.53M-88.2% | -$94.31M-26.4% | ||
| -$166.31M-107% | -$80.49M-16.1% | ||
| -$4.41-71.6% | -$2.57+92.3% | ||
| -$180.56M— | —— | ||
| -$177.53M-88.2% | -$94.31M-26.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does ArriVent BioPharma, Inc.'s income statement data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.